Current pharmacotherapy in the management of cirrhosis: Focus on the hyperdynamic circulation

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 625-637

  Vaughan, Rhys B ^b   Chin Dusting, Jaye P F ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Circulation; Cirrhosis; Hyperdynamic; Nitric oxide; Pharmacotherapy; Portal hypertension

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CEPHALOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENALAPRIL; FUROSEMIDE; ISOSORBIDE MONONITRATE; LOSARTAN; MIDODRINE; MISOPROSTOL; NADOLOL; NIFEDIPINE; NITRIC ACID DERIVATIVE; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PROPRANOLOL; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; TAMOXIFEN; TERLIPRESSIN; TIMOLOL; UNINDEXED DRUG; VASOPRESSIN;

ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BODY TEMPERATURE DISORDER; DISORDERS OF ACID BASE BALANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; ENDOSCOPIC SCLEROTHERAPY; FATIGUE; GYNECOMASTIA; HEART MUSCLE ISCHEMIA; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; IMPOTENCE; INTESTINE ISCHEMIA; KIDNEY CIRCULATION; KIDNEY FAILURE; LIVER CIRCULATION; LIVER CIRRHOSIS; MUSCLE CRAMP; PARACENTESIS; PORTAL HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE; UREMIA; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ASCITES; BLOOD CIRCULATION; DIURETICS; EXPERT TESTIMONY; FEMALE; HUMANS; HYPERTENSION, PORTAL; KIDNEY FAILURE; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE;

EID: 0037797280     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.625     Document Type: Review

References (110)

1. KOWALSKI H, ABELMANN WH: The cardiac output at rest in Laennec's cirrhosis. J. Clin. Invest. (1953) 32:1025-1033.
2. MURRAY JF, DAWSON AM, SHERLOCK S: Circulatory changes in chronic liver disease. Am. J. Med. (1958) 24:358-367.
3. SCHRIER RW, ARROYO V, BERNARDI M, EPSTEIN M, HENRIKSEN JH, RODES J: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 8(5):1151-1157.
4. KONTOS HA, SHAPIRO W, MAUCK HP, PATTERSON JL: General and regional alterations in cirrhosis of the liver. Am. J. Med. (1964) 37:526-535.
5. BRADLEY SE: Variations in hepatic blood flow in man during health and disease. N. Engl. J. Med. (1949) 240:456-461.
6. WYNNE HA, COPE LH, MUTCH E, RAWLINS MD, WOODHOUSE KW, JAMES OF: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 9(2):297-301.
7. WANLESS IR, WONG F, BLENDIS LM, GREIG P, HEATHCOTE PJ, LEVY G: Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology (1995) 21(5):1238-1247.
8. GROSSMAN HJ, GROSSMAN VL, BHATHAL PS: Enhanced vasoconstrictor response of the isolated perfused cirrhotic rat liver to humoral vasoconstrictor substances found in portal venous blood. J. Gatroenterol. Hepatol. (1992) 7(3):283-287.
9. BHATHAL PS, GROSSMAN HJ: Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J. Hepatol. (1985) 1(4):325-337.
10. WIEST R, GROSZMANN RJ: The paradox of nitric oxide in cirrhosis and portal hypertension: too much not enough. Hepatology (2002) 35(2):478-491.
11. ROCKEY DC, CHUNG JJ: Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology (1998) 114(2):344-351.
12. WILLIAMS SG, WESTABY D: Management of variceal haemorrhage. Br. Med. J. (1994) 308(6938):1213-1217.
13. GINES P, FERNANDEZ-ESPARRACH G, ARROYO V, RODES J: Pathogenesis of ascites in cirrhosis. Semin. Liver Dis. (1997) 17(3):175-189.
14. GINES P, MARTIN PY, NIEDERBERGER M: Prognostic significance of renal dysfunction in cirrhosis. Kidney Int. Suppl. (1997) 61:S77-S82.
15. SUCH J, RUNYON BA: Spontaneous bacterial peritonitis. Clin. Infect. Dis. (1998) 27(4):669-674; Quiz 675-676.
16. BICHET DG, VAN PUTTEN VJ, SCHRIER RW: Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N. Engl. J. Med. (1982) 307(25):1552-1557.
17. SCHRIER RW, NIEDERBERGER M, WEIGERT A, GINES P: Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Semin. Liver Dis. (1994) 14(1):14-22.
18. GINES A, ESCORSELL A, GINES P et al.: Incidence predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 105(1):229-236.
19. MERKEL C, BOLOGNESI M, SACERDOTI D et al.: The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2000) 32(5):930-934.
20. KRAVETZ D, SIKULER E, GROSZMANN RJ: Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology (1986) 90(5 Pt 1):1232-1240.
21. HILLON P, LEBREC D, MUNOZ C, JUNGERS M, GOLDFARB G, BENHAMOU JP: Comparison of the effects of a cardioselective and a nonselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology (1982) 2(5):528-531.
22. MILLS PR, RAE AP, FARAH DA, RUSSELL RI, LORIMER AR, CARTER DC: Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut (1984) 25(1):73-78.
23. D'AMICO G, PAGLIARO L, BOSCH J: Pharmacological treatment of portal hypertension: an evidence-based approach. Semin. Liver Dis. (1999) 19(4):475-505.
24. D'AMICO G, PAGLIARO L, BOSCH J: The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 22(1):332-354.
25. ZOLI M C, MERKEL D, MAGALOTTI et al.: Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am. J. Gastroenterol. (2000) 95(2):503-508.
26. BERNARD B, LEBREC D, MATHURIN P, OPOLON P, POYNARD T. β-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology (1997) 25(1):63-70.
27. GONZALEZ SUAREZ B, GUARNER C, MINANA J et al.: Pharmacological treatment of portal hypertension contributes to prevent community-acquired spontaneous bacterial peritonitis (SBP) J. Hepatol. (2000) 32:42A.
28. PEREZ-PARAMO M, MUNOZ J, ALBILLOS A et al.: Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology (2000) 31(1):43-48.
29. LUI HF, STANLEY AJ, FORREST EH et al.: Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation propranolol and isosorbide mononitrate. Gastroenterology (2002) 123(3):735-744.
30. VILLANUEVA C, BALANZO J, NOVELLA MT et al.: Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N. Engl. J. Med (1996) 334(25):1624-1629.
31. VILLANUEVA C, MINANA J, ORTIZ J et al.: Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N. Engl. J. Med. (2001) 345(9):647-655.
32. 1-adrenergic activity has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology (1999) 30(1):79-83.
33. BANARES R, MOITINHO E, MATILLA A et al.: Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology (2002) 36(6):1367-1373.
34. GARCIA-PAGAN JC, NAVASA M, BOSCH J, BRU C, PIZCUETA P, RODES J: Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology (1990) 11(2):230-238.
35. GARCIA-TSAO G, GRACE ND, GROSZMANN RJ et al.: Short-term effects of propranolol on portal venous pressure. Hepatology (1986) 6(1):101-106.
36. HAYES PC, WESTABY D, WILLIAMS R: Effect and mechanism of action of isosorbide-5-mononitrate. Gut (1988) 29(6):752-755.
37. ANGELICO M, CARLI L, PIAT C et al.: Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology (1993) 104(5):1460-1465.
38. ANGELICO M, CARLI L, PIAT C, GENTILE S, CAPOCACCIA L: Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology (1997) 113(5):1632-1639.
39. GROSZMANN RJ: β-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good the bad the ugly. Gastroenterology (1997) 113(5):1794-1797.
40. GARCIA-PAGAN JC, VILLANUEVA C, VILA MC et al.: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers. Gastroenterology (2001) 121(4):908-914.
41. BORRONI G, SALERNO F, CAZZANIGA M et al.: Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J. Hepatol. (2002) 37(3):315-321.
42. KROEGER RJ, GROSZMANN RJ: The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology (1985) 5(3):425-430.
43. MERKEL C, MARIN R, ENZO E et al.: Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Lancet (1996) 348(9043):1677-1681.
44. MERKEL C, GATTA A, DONADA C et al.: Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale. Hepatology (1995) 22(3):808-813.
45. MERKEL C, SACERDOTI D, BOLOGNESI M et al.: Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β-blocker alone. Hepatology (1997) 26(1):34-39.
46. GOURNAY J, MASLIAH C, MARTIN T, PERRIN D, GALMICHE JP: Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology (2000) 31(6):1239-1245.
47. CIRERA I, FEU F, LUCA A et al.: Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology (1995) 22(1):106-111.
48. CHATILA R, FERAYORNI L, GUPTA T, GROSZMANN RJ: Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology (2000) 31(3):572-576.
49. WIEST R, TSAI MH, GROSZMANN RJ: Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology (2001) 120(4):975-983.
50. ALBILLOS A, ROSSI I, IBORRA J et al.: Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J. Hepatol. (1994) 21(1):88-94.
51. GOTZSCHE PC, GJORUP I, BONNEN H, BRAHE NE, BECKER U, BURCHARTH F: Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. Br. Med J. (1995) 310(6993):1495-1498.
52. BURROUGHS AK, MCCORMICK PS, HUGHES MD, SPRENGERS D, D'HEYGERE F, MCINTYRE N: Randomized double-blind placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology (1990) 99(5):1388-1395.
53. ESCORSELL A, BORDAS JM, DEL ARBOL LR et al.: Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group. J. Repatol. (1998) 29(5):779-788.
54. CORLEY DA, CELLO JP, ADKISSON W, KO WF, KERLIKOWSKE K: Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology (2001) 120(4):946-954.
55. AVGERINOS A, NEVENS F, RAPTIS S, FEVERY J: Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet (1997) 350(9090):1495-1499.
56. BOSCH J, BORDAS JM, MASTAI R et al.: Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure. Hepatology (1988) 8(4):861-865.
57. BOSCH J, GROSZMANN JR, GARCIA-PAGAN JR et al.: Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial. Hepatology (1989) 10(6):962-968.
58. IOANNOU GN, DOUST J, ROCKEY DC: Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment. Pharmacol. Ther. (2003) 17(1):53-64.
59. ESCORSELL A, RUIZ L, DEL ARBOL LR, PLANAS R et al.: Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 32(3):471-476.
60. GOULIS J, PATCH D, BURROUGHS AK: Bacterial infection in the pathogenesis of variceal bleeding. Lancet (1999) 353(9147):139-142.
61. SORIANO G, GUARNER. C, TOMAS A et al.: Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology (1992) 103(4):1267-1272.
62. BERNARD B, GRANGE JD, KHAC EN, AMIOT X, OPOLON P, POYNARD T: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 29(6):1655-1661.
63. BOSCH J V ARROYO A BETRIU et al.: Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology (1980) 78(1):92-99.
64. CHIANG HT, CHENG JS, LIN M, TSENG WS, CHANG JM, LAI KH: Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J. Gastroenterol. Hepatol. (1995) 10(3):256-260.
65. PARIENTE EA, BATAILLE C, BERCOFF E, LEBREC D: Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology (1985) 88(5 Pt 1):1255-1259.
66. ARROYO V, BOSCH J, MAURI M, RIBERA F, NAVARRO-LOPEZ F, RODES J: Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur. J. Clin. Invest. (1981) 11(3):221-229.
67. SCHNEIDER AW, KALK JF, KLEIN CP: Effect of losartan an angiotensin II receptor antagonist on portal pressure in cirrhosis. Hepatology (1999) 29(2):334-339.
68. SCHEPKE M, WERNER E, BIECKER E et al.: Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology (2001) 121(2):389-395.
69. GONZALEZ-ABRALDES J, ALBILLOS A, BANARES R et al.: Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology (2001) 121(2):382-388.
70. REICHEN J, LE M: Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J. Clin. Invest. (1986) 78(2):448-455.
71. VINEL JP, CAUCANAS JP, COMBIS JM, CALES P, VOIGT JJ, PASCAL JP: Verapamil has no effect on porto-hepatic pressure gradient hepatic blood flow and elimination function of the liver in patients with liver cirrhosis. J. Hepatol. (1989) 8(3):302-307.
72. NAVASA M, BOSCH J, REICHEN J et al.: Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology (1988) 8(4):850-854.
73. IWAO T, TOYONAGA A, IKEGAMI M et al.: Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis. Am. J. Gastroenterol. (1992) 87(3):326-331.
74. GARCIA-PAGAN JC, FEU F, LUCA A et al.: Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis. J. Hepatol. (1994) 20(6):792-796.
75. KOSHY A, HADENGUE A, LEE SS, JIRON MI, LEBREC D: Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis. Clin. Pharmacol. Ther. (1987) 42(3):295-298.
76. RUNYON BA: Care of patients with ascites. N. Engl. J. Med. (1994) 330(5):337-342.
77. GERBES AL: Medical treatment of ascites in cirrhosis. J. Hepatol. (1993) 17(Suppl. 2):S4-S9.
78. SALO J, GUEVARA M, FERNANDEZ-ESPARRACH G et al.: Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems. Hepatology (1997) 25(6):1338-1342.
79. SALO J, GINES A, ANIBARRO L et al.: Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin aldosterone and norepinephrine levels. Hepatology (1995) 22(2):479-487.
80. RUNYON BA: Refractory ascites. Semin. Liver Dis. (1993) 13(4):343-351.
81. GINES A, FERNANDEZ-ESPARRACH G, MONESCILLO A et al.: Randomized trial comparing albumin dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology (1996) 111(4):1002-1010.
82. GINES P, GUEVARA M, DE LAS HERAS D, ARROYO V: Review article: albumin for circulatory support in patients with cirrhosis. Aliment. Pharmacol. Ther. (2002) 16(Suppl. 5):24-31.
83. PEREZ-AYUSO RM, ARROYO V, PLANAS R et al.: Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology (1983) 84(5 Pt 1):961-968.
84. FOGEL MR, SAWHNEY VK, NEAL EA, MILLER RG, KNAUER CM, GREGORY PB: Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J. Clin. Gastroenterol. (1981) 3(Suppl. 1):73-80.
85. LI CP, LEE FY, HWANG SJ et al.: Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. Am. J. Gastroenterology (2000) 95(4):1051-105.
86. ANGELI P, DALLA PRIA M, DE BEI E et al.: Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology (1994) 19(1):72-79.
87. RUNYON BA: Management of adult patients with ascites caused by cirrhosis. Hepatology (1998) 27(1):264-272.
88. SORT P, NAVASA M, ARROYO V et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. (1999) 341(6):403-409.
89. NAVASA M, FOLLO A, LLOVET JM et al.: Randomized comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 111(4):1011-1017.
90. TERG R, COBAS S, FASSIO E et al.: Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter randomized study. J. Hepatol. (2000) 33(4):564-569.
91. TITO L, RIMOLA A, GINES P, LLACH J, ARROYO V, RODES J: Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology (1988) 8(1):27-31.
92. GINES P, RIMOLA A, PLANAS R et al.: Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind placebo-controlled trial. Hepatology (1990) 12(4 Pt 1):716-724.
93. HADENGUE A, GADANO A, MOREAU R et al.: Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol. (1998) 29(4):565-570.
94. HALIMI C, BONNARD P, BERNARD B et al.: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur. J. Gastroenterol. Hepatol. (2002) 14(2):153-158.
95. MOREAU R, DURAND F, POYNARD T et al.: Terlipressin in patients with cirrhosis and Type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 122(4):923-930.
96. ORTEGA R, GINES P, URIZ J et al.: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective nonrandomized study. Hepatology (2002) 36(4 Pt 1):941-948.
97. KAFFY F, BORDERIE C, CHAGNEAU C et al.: Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. J. Hepatol. (1999) 30(1):174.
98. ANGELI P, VOLPIN R, GERUNDA G et al.: Reversal of Type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology (1999) 29(6):1690-1697.
99. GINES A, SALMERON JM, GINES P et al.: Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J. Hepatol. (1993) 17(2):220-226.
100. BENNETT WM, KEEFFE E, MELNYK C, MAHLER D, ROSCH J, PORTER GA: Response to dopamine hydrochloride in the hepatorenal syndrome. Arch. Intern. Med. (1975) 135(7):964-971.
101. HOLT S, GOODIER D, MARLEY R et al.: Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet (1999) 353(9149):294-295.
102. VAUGHAN RB, CHIN-DUSTING JP, DUDLEY FJ, ANGUS PW: Peripheral vasodilatation following endothelin-1 infusion in patients with decompensated cirrhosis. Hepatology (2000) 32(4):403A.
103. SOPER CP, LATIF AB, BENDING MR: Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet (1996) 347(9018):1842-1843.
104. VALLANCE P, MONCADA S: Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet (1991) 337(8744):776-778.
105. ALBILLOS A, DE LA HERA A, GONZALEZ M et al.: Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology (2003) 37(1):208-217.
106. CHIN-DUSTING JP, RASARATNAM B, JENNINGS GL, DUDLEY FJ: Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann. Intern. Med. (1997) 127(11):985-988.
107. RASARATNAM B, KAYE DM, JENNINGS GL, DUDLEY F, CHIN-DUSTING JP: Selective intestinal decontamination ameliorates the hyperdynamic circulatory state in patients with hepatic cirhosis. Ann. Intern. Med. (In Press).
108. GUYADER D, PATAT A, ELLIS-GROSSE EJ, ORCZYK GP: Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology (2002) 36(5):1197-1205.
109. WONG F, BLEI AT, BLENDIS LM, THULUVATH PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter randomized placebo-controlled trial. Hepatology (2003) 37(1):182-191.
110. FIORUCCI S, ANTONELLI E, MORELLI O et al.: NCX-1000 a NO releasing derivative of ursodeoxycholic acid selectively delivers NO to the liver and protects against development of portal hypertension. Proc. Natl. Acad. Sci. USA (2001) 98(15):8897-8902.